ICU - Wutah dodolan YoY sajrone 12 wulan kepungkur SeaStar Medical Holding Corp.

Year-over-year revenue dynamics over the last 12 months demonstrate the development of the SCD system for combating hyperinflammation in renal pathologies, with the value holding at 146.10. SeaStar Medical Holding (ICU) is implementing selective blood purification methods for adults and children. High barriers to entry, provided by exclusive patents and strict FDA control, guarantee the market stability of SeaStar Medical Holding (ICU).
Ringkesan rincian data analitis SeaStar Medical (ICU)

Strategic alliances between SeaStar Medical Holding (ICU) and pediatric clinics to implement cytokine blood purification systems are driving revenue dynamics. The current year-over-year (TTM) revenue growth rate measures the percentage change in the trailing twelve-month sales on a daily basis. This metric objectifies the pace of business expansion by eliminating seasonal distortions. A steady upward trend confirms the commercial effectiveness of clinical trials, while a decline in the indicator could signal stagnation in market value.